Cutaneous Cancer

Melanoma:

CIRB #H-38640/ SWOG #S1801: A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant  Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma

CIRB #H-41279/ CTSU #EA6191 (PET-stop): A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) (pending)